Denver News Updates

Diabetic Peripheral Neuropathy Pipeline Analysis: Key Companies and Emerging Therapies

 Breaking News
  • No posts were found

Diabetic Peripheral Neuropathy Pipeline Analysis: Key Companies and Emerging Therapies

June 03
12:48 2020
Diabetic Peripheral Neuropathy Pipeline Analysis: Key Companies and Emerging Therapies

Diabetic Peripheral Neuropathy Pipeline

The most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided, which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines.

The assessment part of the report embraces in-depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the Diabetic Peripheral Neuropathy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Request for Sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight

Diabetic Peripheral Neuropathy Pipeline  

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.

In the pipeline

  1. VM202
  2. NYX-2925
  3. WST-057
  4. Ricolinostat
  5. ISC 17536
  6. NRD135S.E1
  7. Cebranopadol
  8. GRC 17356
  9. MEDI7352
  10. Trazodone/Gabapentin

And many others

Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also  expected to enter the market by 2030 as effective therapies.

The key pharma players working in Diabetic Peripheral Neuropathy Market are:

  1. Helixmith,
  2. Aptinyx
  3. WinSanTor, Inc
  4. Regenacy Pharmacuticals
  5. Ichnos Science
  6. Novaremed
  7. Grünenthal GmbH
  8. Glenmark Pharmaceuticals
  9. AstraZeneca
  10. Angelini

And many others

 

Table of Contents

1. Report Introduction

2. Diabetic Peripheral Neuropathy 

3. Diabetic Peripheral Neuropathy Current Treatment Patterns

4. Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diabetic Peripheral Neuropathy Late Stage Products (Phase-III)

7. Diabetic Peripheral Neuropathy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetic Peripheral Neuropathy Discontinued Products

13. Diabetic Peripheral Neuropathy Product Profiles

14. Diabetic Peripheral Neuropathy Key Companies

15. Diabetic Peripheral Neuropathy Key Products

16. Dormant and Discontinued Products

17. Diabetic Peripheral Neuropathy Unmet Needs

18. Diabetic Peripheral Neuropathy Future Perspectives

19. Diabetic Peripheral Neuropathy Analyst Review  

20. Appendix

21. Report Methodology

 

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

Browse through our vast repository

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/